Literature DB >> 23709694

Cbl-b mediates TGFβ sensitivity by downregulating inhibitory SMAD7 in primary T cells.

Thomas Gruber1, Reinhard Hinterleitner, Natascha Hermann-Kleiter, Marlies Meisel, Ingo Kleiter, Chiuhui Mary Wang, Antonella Viola, Christa Pfeifhofer-Obermair, Gottfried Baier.   

Abstract

T cell-intrinsic transforming growth factor β (TGFβ) receptor signaling plays an essential role in controlling immune responses. The RING-type E3 ligase Cbl-b has been shown to mediate the sensitivity of T cells to TGFβ; however, the mechanism underlying this process is unknown. This study shows that SMAD7, an established negative regulator of TGFβ receptor (TGFβR) signaling, is a key downstream effector target of Cbl-b. SMAD7 protein levels, but not SMAD7 mRNA levels, are upregulated in cblb(-/-) T cells. Cbl-b directly interacts with and ubiquitinates SMAD7, suggesting that Cbl-b posttranscriptionally regulates SMAD7. In support of this notion, concomitant genetic loss of SMAD7 in cblb(-/-) mice restored TGFβ sensitivity on T cell cytokine responses and abrogated the tumor rejection phenotype of cblb(-/-) mice. These results demonstrate an essential and non-redundant role for Cbl-b in controlling TGFβR signaling by directly targeting SMAD7 for degradation during T cell responses in vitro and in vivo.

Entities:  

Keywords:  Cbl-b; SMAD; TGFβ signaling

Mesh:

Substances:

Year:  2013        PMID: 23709694     DOI: 10.1093/jmcb/mjt017

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  18 in total

1.  TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.

Authors:  Vidhyalakshmi Arumugam; Theresa Bluemn; Erin Wesley; Amanda M Schmidt; Taku Kambayashi; Subramaniam Malarkannan; Matthew J Riese
Journal:  J Leukoc Biol       Date:  2015-07-07       Impact factor: 4.962

2.  Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.

Authors:  Mai Fujiwara; Emily J Anstadt; Kamal M Khanna; Robert B Clark
Journal:  Clin Immunol       Date:  2015-03-28       Impact factor: 3.969

3.  Lys63-polyubiquitination by the E3 ligase casitas B-lineage lymphoma-b (Cbl-b) modulates peripheral regulatory T cell tolerance in patients with systemic lupus erythematosus.

Authors:  J Romo-Tena; S Rajme-López; L Aparicio-Vera; J Alcocer-Varela; D Gómez-Martín
Journal:  Clin Exp Immunol       Date:  2017-10-19       Impact factor: 4.330

4.  Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth.

Authors:  X Li; Y Kang; D Roife; Y Lee; M Pratt; M R Perez; B Dai; E J Koay; J B Fleming
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

Review 5.  Ubiquitous points of control over regulatory T cells.

Authors:  Fan Pan; Joseph Barbi
Journal:  J Mol Med (Berl)       Date:  2014-04-29       Impact factor: 4.599

Review 6.  E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy.

Authors:  D Jafari; M J Mousavi; S Keshavarz Shahbaz; L Jafarzadeh; S Tahmasebi; J Spoor; A Esmaeilzadeh
Journal:  Clin Exp Immunol       Date:  2021-01-10       Impact factor: 5.732

Review 7.  Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.

Authors:  Christina Lutz-Nicoladoni; Dominik Wolf; Sieghart Sopper
Journal:  Front Oncol       Date:  2015-03-11       Impact factor: 6.244

8.  The multifunctional adaptor protein HIP-55 couples Smad7 to accelerate TGF-β type I receptor degradation.

Authors:  Yang Sun; Zi-Jian Li
Journal:  Acta Pharmacol Sin       Date:  2021-07-30       Impact factor: 6.150

Review 9.  Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.

Authors:  Xiaoli Hu; Jing Wang; Man Chu; Yi Liu; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Ther       Date:  2021-01-01       Impact factor: 11.454

10.  Tumor rejection in Cblb -/- mice depends on IL-9 and Th9 cells.

Authors:  Oliver Schanz; Isabelle Cornez; Sowmya Parampalli Yajnanarayana; Friederike Sophie David; Sebastian Peer; Thomas Gruber; Peter Krawitz; Peter Brossart; Annkristin Heine; Jenny Landsberg; Gottfried Baier; Dominik Wolf
Journal:  J Immunother Cancer       Date:  2021-07       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.